These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 34560556)

  • 21. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
    Wang C; Li X; Zhang L; Chen Y; Dong R; Zhang J; Zhao J; Guo X; Yang G; Li Y; Gu C; Xi Q; Zhang R
    Int Immunopharmacol; 2021 Aug; 97():107822. PubMed ID: 34098485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma.
    Chen XY; Zhang J; Hou LD; Zhang R; Chen W; Fan HN; Huang YX; Liu H; Zhu JS
    Int J Immunopathol Pharmacol; 2018; 32():2058738418790318. PubMed ID: 30045644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
    Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
    Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells.
    Almeida MI; Nicoloso MS; Zeng L; Ivan C; Spizzo R; Gafà R; Xiao L; Zhang X; Vannini I; Fanini F; Fabbri M; Lanza G; Reis RM; Zweidler-McKay PA; Calin GA
    Gastroenterology; 2012 Apr; 142(4):886-896.e9. PubMed ID: 22240480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
    Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
    J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p.
    Zhou WY; Zhang MM; Liu C; Kang Y; Wang JO; Yang XH
    J Cell Physiol; 2019 Dec; 234(12):23176-23189. PubMed ID: 31206665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mifepristone inhibited tumor progression by disrupting the stability of PD-L1 by miR-127-3p/VAMP2 in ovarian cancer.
    Gu Y; Zhang Y; Liu J
    Pak J Pharm Sci; 2022 Jan; 35(1(Special)):393-400. PubMed ID: 35236654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
    Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
    J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The aminophospholipid transporter, ATP8B3, as a potential biomarker and target for enhancing the therapeutic effect of PD-L1 blockade in colon adenocarcinoma.
    Zhang W; Xie Y; Liu Z; Zhang J; Ni B; Gao W; Xing W; Zhou Y; Si T
    Genomics; 2024 Sep; 116(5):110907. PubMed ID: 39074670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
    Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
    Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
    Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
    Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc.
    Anastasiadou E; Messina E; Sanavia T; Mundo L; Farinella F; Lazzi S; Megiorni F; Ceccarelli S; Pontecorvi P; Marampon F; Di Gioia CRT; Perniola G; Panici PB; Leoncini L; Trivedi P; Lenzi A; Marchese C
    Cells; 2021 Mar; 10(3):. PubMed ID: 33804458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR-10b-5p Impairs TET2-Mediated Inhibition of PD-L1 Transcription Thus Promoting Immune Evasion and Tumor Progression in Glioblastoma.
    Du W; Chen D; Wei K; Yu D; Gan Z; Xu G; Yao G
    Tohoku J Exp Med; 2023 Jul; 260(3):205-214. PubMed ID: 37019647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted delivery of anti-miRNA21 sensitizes PD-L1
    Kim EH; Choi J; Jang H; Kim Y; Lee JW; Ryu Y; Choi J; Choi Y; Chi SG; Kwon IC; Yang Y; Kim SH
    Theranostics; 2024; 14(10):3777-3792. PubMed ID: 38994018
    [No Abstract]   [Full Text] [Related]  

  • 38. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
    Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
    Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathological Complete Response to Liver Metastasis With Pembrolizumab in a Previously Treated Patient With Microsatellite Instability-high Colorectal Cancer.
    Hosokawa A; Tamura H; Ichihara A; Imamura N; Kai K; Fukushima T; Nanashima A; Komohara Y
    Anticancer Res; 2024 Sep; 44(9):4119-4125. PubMed ID: 39197935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant promoter hypermethylation of miR-335 and miR-145 is involved in breast cancer PD-L1 overexpression.
    Hajibabaei S; Sotoodehnejadnematalahi F; Nafissi N; Zeinali S; Azizi M
    Sci Rep; 2023 Jan; 13(1):1003. PubMed ID: 36653507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.